Figures and Tables

From the following article:

Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Roy Pettipher, Trevor T. Hansel & Richard Armer

Nature Reviews Drug Discovery 6, 313-325 (April 2007)

doi:10.1038/nrd2266

Figure 1 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 1

Pathways of PGD2 metabolism.

Figure 2 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 2

Proposed scheme describing the role of mast-cell-derived PGD2 in the polarization and activation of TH2 lymphocytes, effects achieved through combined action on DP1 and CRTH2 receptors.

Figure 3 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 3

PGD2 and related prostanoids.

Figure 4 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 4

NSAIDs used as starting points for the design of selective CRTH2 antagonists.

Figure 5 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 5

Ramatroban analogues with CRTH2 antagonist activity.

Figure 6 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 6

Physicogenetically identified CRTH2 antagonists.

Figure 7 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 7

Indole-acetic-acid based compounds with CRTH2 antagonist activity.

Figure 8 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 8

Aryl acetic acid CRTH2 antagonists.

Figure 9 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Figure 9

Non-acidic CRTH2 antagonists.

Table 1 - Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

Table 1

Comparison of the key biological and pharmacological properties of CRTH2, DP1 and TP